ONC Earnings & Financial Statements
BeOne Medicines Ltd.
$377.63
-$4.64(-1.21%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
307.78K
52W Range
$253.95 - $385.22
Target Price
--
ONC earnings and financial statements: BeOne Medicines Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ONC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Cost of revenue | $668.54M | $594.09M | - | $286.48M | $164.91M |
| Operating income | $447.14M | -$568.20M | -$1.21B | -$1.79B | -$1.44B |
| EBITDA | $616.77M | -$339.43M | -$812.17M | -$2.04B | -$1.39B |
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | -$1.46B |
| EPS (diluted) | $0.19 | $-6.11 | $-8.45 | $-1.49 | $-1.17 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | $8.54B |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2.00B | $2.40B |
| Shareholders’ equity | $4.36B | $3.33B | $3.54B | $4.38B | $6.13B |
| Cash and equivalents | $4.55B | $2.63B | $3.17B | $3.87B | $4.38B |
| Long-term debt | $1.01B | $210.76M | $1.42B | $1.48B | $1.33B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.13B | -$140.63M | -$1.16B | -$1.50B | -$1.30B |
| Capital expenditure | -$205.84M | -$497.34M | -$596.26M | -$469.10M | -$314.85M |
| Free cash flow | $921.74M | -$637.97M | -$1.74B | -$1.97B | -$1.61B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ONC | $377.63 | -1.2% | 307.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |